Clinical trial NCT05891834: Study of INV-202 in Patients With Obesity and Metabolic Syndrome
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of 3 Doses of INV-202 With an Optional Open-Label Extension in Patients With Obesity and Metabolic Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Obesity
Metabolic Syndrome
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2023-06-07
Enrollment: 243
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with obesity and metabolic syndrome.

Detailed description: This will be a 2-part study. Part A will be a randomized, double-blind, placebo-controlled, dose ranging, multicenter study assessing the efficacy, safety, tolerability, and PK of INV-202 for the treatment of adult participants with obesity (BMI 30 kg/m2) and metabolic syndrome.

An informed consent form (ICF) must be signed by the participant before any study-related procedures are performed.

Each participant will be allowed 1 retest during the screening period if they have an abnormal test result not meeting eligibility criteria that is deemed transient by the investigator. Participants who did not meet all eligibility criteria may be re-screened once, with approval of the medical monitor.

Participants will return to the study site at Weeks 4, 8, 12 and 16. At these visits, the same assessment as baseline will be completed.

During Part A, a subset of approximately 20 to 30 participants from an estimated 3 to 4 study sites will have DEXA performed at baseline and Week 16 for exploratory assessments of change in total body fat percentage and skeletal muscle mass. Additional exploratory measures will include lung function with oscillometry. Any participant who withdraws from Part A before completing treatment will be requested to return for an early termination visit, at which time the procedures normally scheduled for the Week 16 visit will be conducted.

Participants completing Part A will be eligible to enroll to the open-label extension (OLE), Part B, if they did not have significant noncompliance with study drug, visits, or procedures, and did not meet any withdrawal criteria. During Part B, the efficacy and safety of INV-202 20 mg daily (pending results of chronic toxicology studies and/or findings from this and other ongoing clinical studies, the alternative dose would be 10 mg) will be further evaluated over an additional 36 weeks, through Week 52.

Eligibility criteria: Inclusion Criteria:

1. Male and female participants from 18 to 75 years of age 2. Able and willing to provide informed consent and to comply with scheduled visits and study procedures 3. BMI ≥ 30 kg/m2 4. Presence of at least 3 of the 5 following criteria at screening: i. Increased waist circumference (males, ≥40 inches; females, ≥35 inches) ii. Fasting glucose ≥ 100 mg/dL in the last 3 months or an HgbA1C \> 5.7% iii. Triglycerides ≥ 150 mg/dL or 1.69 mmol/L iv. HDL \< 40 mg/dL or 1.03 mmol/L for males or \< 50 mg/dL or 1.29 mmol/L for females v. Hypertension (systolic \>130 mmHg and/or diastolic \> 85 mmHg) or treated for hypertension

Exclusion Criteria:

1. Significant medical condition, that in the opinion of the investigator, will place the participant at risk during the study or that will confound the study endpoints
2. Active substance abuse including inhaled, oral, or injection drugs in the past 12 months
3. Use of cannabis or cannabinoid-containing compounds within 90 days prior to screening
4. Pregnancy, planned pregnancy, potential for pregnancy, breast feeding, or unwillingness to use highly effective birth control during the study
5. History of significant liver disease or evidence of moderate to severe hepatic impairment
6. History of epilepsy or intracranial surgery
7. Diabetes requiring medication for management (a diagnosis of diabetes that is well controlled with diet and exercise is not exclusionary)
8. Bariatric surgery, use of a GLP-1 agonists or other weight-loss drug, or significant weight change (\> 5 kg or 11 pounds) in the past 3 months
9. Participants taking any drug that may be used for weight loss (eg, liraglutide, semaglutide, tirzepatide, orlistat sibutramine phenylpropanolamine , mazindol , phentermine alone or in combination with topiramate, lorcaserin , naltrexone in combination with bupropion)
10. Use of systemic corticosteroids (topical and inhaled corticosteroids are not excluded)
11. Participants with an active diagnosis or history of a significant psychiatric disorder, including but not limited to the following:

    Major depression within the last 2 years
    * Any history of a suicide attempt or suicidal ideation
    * A history of other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)
    * Taking any of the following medications: antidepressants, atypical antipsychotics and mood stabilizers such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, lithium
12. Score on the 9-question Patient Health Questionnaire (PHQ-9) of
13. Current or active malignancy within the past 5 years, except for cancer in situ, or nonmelanoma skin cancer, such as basal cell or squamous cell carcinoma that has been completely resected
14. A history thyroid disease; the only exception would be a participant who has undergone a complete thyroid ablation/resection
15. QTc \> 500 ms at baseline
16. Any chronic medications with effects on blood pressure, lipids, or blood glucose started or changed within the past 3 months or at risk of requiring a change during the study
17. Participants taking a strong inducer or inhibitor of cytochrome P450 3A4, 2D6, or 2C19 by screening; these medications are prohibited during the entire duration of the study
18. Having taken any investigational compound within 30 days, or 5 half-lives of the drug, whichever is longer, before the screening visit
19. Previous use of INV-202
20. Participants that, in the opinion of the investigator, are unsuitable for the study or unlikely to comply with all study procedures and treatment

Primary outcomes:
measure: To evaluate the effect of INV-202 on body weight loss in participants with obesity and metabolic syndrome
timeFrame: Week 16
Secondary outcomes:
measure: To evaluate the effect of INV-202 on weight (marker of metabolic syndrome)
timeFrame: Week 16
measure: To evaluate the effect of INV-202 on waist circumference (marker of metabolic syndrome)
timeFrame: Week 16
measure: To evaluate the effect of INV-202 on lipids (marker of metabolic syndrome)
timeFrame: Week 16
measure: To evaluate the effect of INV-202 on glucose control (marker of metabolic syndrome)
timeFrame: Week 16
measure: To evaluate the effect of INV-202 on glucose control (marker of metabolic syndrome)
timeFrame: Week 16
measure: To evaluate the effect of INV-202 on glucose control (marker of metabolic syndrome)
timeFrame: Week 16
Other outcomes:
Locations:
city: New Westminster
country: Canada
facility: Office of David H. Shu, MD
state: British Colombia
city: New Minas
country: Canada
facility: Centricity Research -New Minas
state: Nova Scotia
city: Brampton
country: Canada
facility: Aggarwal and Associates, Limited
state: Ontario
city: Hamilton
country: Canada
facility: Wharton Medical Clinic (WMC) - Toronto
state: Ontario
city: London
country: Canada
facility: Milestone Research Inc
state: Ontario
city: Oshawa
country: Canada
facility: Centricity Research - Oshawa
state: Ontario
city: Sarnia
country: Canada
facility: Bluewater Clinical Research Group Inc
state: Ontario
city: Toronto
country: Canada
facility: Canadian Phase Onward Inc.
state: Ontario
city: Toronto
country: Canada
facility: Dr. Anil K. Gupta Medicine Professional Corporation
state: Ontario
city: Waterloo
country: Canada
facility: Dr. Sameh Fikry Medicine Professional Corporation
state: Ontario
city: Waterloo
country: Canada
facility: Clinical Research Solutions
state: Ontario
city: Chicoutimi
country: Canada
facility: Ecogene-21
state: Quebec
city: Joliette
country: Canada
facility: DIEX Research Joliette
state: Quebec
city: Lévis
country: Canada
facility: Centricity Research - Levis
state: Quebec
city: Mirabel
country: Canada
facility: Centricity Research - Mirabel
state: Quebec
city: Montréal
country: Canada
facility: 9109-0126 Quebec Inc
state: Quebec
city: Pointe-Claire
country: Canada
facility: Centricity Research - Pointe-Claire
state: Quebec
city: Québec
country: Canada
facility: DIEX Research Quebec
state: Quebec
city: Québec
country: Canada
facility: Centre des maladies lipidique deq Quebec, CMLQ Inc.
state: Quebec
city: Québec
country: Canada
facility: Alpha Recherche Clinique - Lebourgneuf
state: Quebec
city: Québec
country: Canada
facility: Alpha Recherche Clinique Val-Bélair
state: Quebec
city: Sherbrooke
country: Canada
facility: Diex Recherche Sherbrooke
state: Quebec
city: Trois-Rivières
country: Canada
facility: Diex Recherche Trois-Rivieres
state: Quebec
city: Victoriaville
country: Canada
facility: Diex Recherche Victoriaville
state: Quebec
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Transparency (dept. 2834)
role: STUDY_DIRECTOR
References: